Skip to main content

DCI Blog
Events
DCI Members
Contact

Cancer Types

All Cancers
Primary Brain Cancer
Brain and Spine Metastasis
Breast Cancer
Endocrine Neoplasia
Gastrointestinal Cancer
Gynecologic Cancer
Head and Neck Cancer
Hematologic Malignancies and Cellular Therapy
Melanoma and Advanced Skin Cancers
Pediatric Cancers
Prostate and Urologic Cancers
Sarcoma
Thoracic Cancer

Cancer Therapies
Immunotherapy
Molecular Tumor Board

Supportive Care

Supportive Care and Survivorship Center

Research

Cancer Registry
Clinical Trials
Research Programs
Shared Resources

Education and Training

Office of Cancer Research Training and Education Coordination

About DCI

DCI Overview
DCI Members
Nursing
Careers
Community Outreach, Engagement, and Equity
Office of Equity, Diversity, and Inclusion
Contact
DCI blog
Events

Give to DCI

Giving Opportunities
Benefits and Special Events
Breakthroughs Magazine

Make an Appointment

Blogs

Poliovirus Therapy for Recurrent Glioblastoma Has Three-Year Survival Rate of 21 Percent

Updated

August 14, 2023

Written By

Sarah Avery

Director, Duke Health News Office

Topics

Preston Robert Tisch Brain Tumor Center
Research
Clinical Trials

Share

Share This Page

Print Page Or Copy Link Url

Copied to clipboard

Related News

NewsMention_CristieFelix

News Mention

A Story of Hope: Cristie Felix

June 05, 2024

Duke Neurosurgery

Ines Batinic Haberle hold up a vial of BMX-001 in her lab

Dr. Ines Batinic Haberle in her lab with a vial of BMX-001, a synthetic form of superoxide dismutase.

News Mention

Duke Drug Improves Survival in Advanced Brain Cancer Patients

February 07, 2024

Duke University School of Medicine

Related News

NewsMention_CristieFelix

News Mention

A Story of Hope: Cristie Felix

June 05, 2024

Duke Neurosurgery

Ines Batinic Haberle hold up a vial of BMX-001 in her lab

Dr. Ines Batinic Haberle in her lab with a vial of BMX-001, a synthetic form of superoxide dismutase.

News Mention

Duke Drug Improves Survival in Advanced Brain Cancer Patients

February 07, 2024

Duke University School of Medicine

Website Privacy Policy
Sitemap
Duke Health Anti-Racism Pledge
Notice on Nondiscrimination
Notice of Privacy Practices
Terms and Conditions
Accessibility
© DUKE CANCER INSTITUTE 2024

Back to Top